Botanix has treated the first patient in its BTX 1308 psoriasis Phase 1b patient study
Key highlights
· Botanix has treated the first patient in its BTX 1308 psoriasis Phase 1b patient study
· Study is being conducted in partnership with international psoriasis model experts - Bioskin GmbH, using their unique clinically validated system
· Study represents the 3rd clinical program to commence within 12 months for Botanix, demonstrating the Company’s ability to accelerate the addition of clinical programs across a range of skin diseases
Philadelphia PA and Sydney Australia, 7 November 2018: Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “The Company”)is pleased to announce the treatment of the first patient in its Phase 1b BTX 1308 psoriasis patient study. The study is testing a new formulation of synthetic cannabidiol combined with the Company’s novel Permetrex skin delivery technology.
The ASX announcement can be viewed here
Have you seen our earlier videos?
Click here to visit our YouTube page
Click here to watch an introduction to Botanix Pharmaceuticals
Click here to watch the BTX 1204 Presentation
Click here to watch an interview with CMO, Dr Stephane Levy
For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma
General Enquiries
Matt Callahan
Botanix Pharmaceuticals
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com
Investor Enquiries
Joel Seah
Vesparum Capital
P: +61 3 8582 4800
E: botanixpharma@vesparum.com
Media Enquiries
Julia Maguire
The Capital Network
P: +61 419 815 386
E: julia@thecapitalnetwork.com.au
